620 reports of this reaction
3.3% of all AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE reports
#1 most reported adverse reaction
NAUSEA is the #1 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 620 FDA adverse event reports linking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE to NAUSEA. This represents approximately 3.3% of all 18,930 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 620 FDA reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 3.3% of all adverse event reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience nausea while taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.